Acutaas Chemicals Latest Share Price (ACUTAAS)
TODAY IN ONE LINE
ACUTAAS jumped 4.4% on average volume, outperforming Nifty's 0.5% move, supported by recent strong earnings.
With a market cap of ₹27,017.47 Cr., it trades at a P/E of 67.17. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
Acutaas Chemicals flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Earnings GrowthEPS (TTM) grew by a solid 105.6% YoY
- ●Quarterly OutperformanceLatest quarter Sales up 40.3% and Profit up 111.0%
- ●High Capital EfficiencyROCE of 31.6% indicating pricing power
- ●Strong Return on EquityHealthy ROE of 24.0%
- ●Healthy Operating MarginsOPM is structurally strong at 35.9%
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.02x
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Expensive ValuationTrading at a high P/E ratio of 82.3x
Latest Acutaas Chemicals News
What changed recently?
Recent events, corporate actions, and announcements.
Acutaas Chemicals Limited valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Acutaas Chemicals Limited, framed against the sector median so the premium or discount is obvious at a glance.
Acutaas Chemicals Limited trades at a P/E of 67.17× and P/B of 15.69×, against the Healthcare sector median P/E of 45.32×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
Acutaas Chemicals Limited technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for Acutaas Chemicals Limited — derived from the latest tape, not yesterday's close.
Acutaas Chemicals Limited last traded at ₹3,313.4 with an intraday range of ₹3,138–₹3,325 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹3313.40| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 3753.60 | +440.20 | +13.29% |
| R3 | 3566.60 | +253.20 | +7.64% |
| R2 | 3445.80 | +132.40 | +4.00% |
| R1 | 3379.60 | +66.20 | +2.00% |
| PIVOT | 3258.80 | -54.60 | -1.65% |
| CURRENT | 3313.40 | — | — |
| S1 | 3192.60 | -120.80 | -3.65% |
| S2 | 3071.80 | -241.60 | -7.29% |
| S3 | 3005.60 | -307.80 | -9.29% |
| S4 | 2818.60 | -494.80 | -14.93% |
ACUTAAS is trading Above CPR, indicating Bullishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: ₹3157–₹3217.5
Trading Above opening range, showing Bullishness
Acutaas Chemicals Limited financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for Acutaas Chemicals Limited — consolidated or standalone — with margins, YoY growth and key ratios inline.
Acutaas Chemicals Limited reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹27,017.47 Cr. and reported EPS of ₹34.90.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 1,007 | 1,339 ▲ 33.0% |
| Sales Growth YoY %Derived | 40.34% | 33.02% |
| Other Income | 17 | 42 ▲ 145.6% |
| Total Income | 1,024 | 1,381 ▲ 34.9% |
| 552 | 566 ▲ 2.5% | |
| Gross ProfitDerived | 455 | 773 ▲ 70.1% |
| Gross Margin %Derived | 45.16% | 57.74% |
| 223 | 293 ▲ 31.6% | |
| EBITDA (Operating Profit)Derived | 232 | 480 ▲ 107.0% |
| OPM %Derived | 23.05% | 35.87% |
| 33 | 39 ▲ 19.5% | |
| Profit Before Tax (PBT) | 216 | 483 ▲ 123.3% |
| 56 | 126 ▲ 126.7% | |
| Effective Tax %Derived | 25.79% | 26.18% |
| Total Profit for Period | 160 | 356 ▲ 122.2% |
| Less: Non-controlling Interests | 2 | 0 ▼ 93.3% |
| Net Profit (Owner's PAT)Derived | 159 | 356 ▲ 124.5% |
| Net Profit Margin %Derived | 15.76% | 26.60% |
| PAT Growth YoY %Derived | 271.06% | 124.46% |
| Earnings Per Share (EPS ₹) | 19.39 | 43.51 ▲ 124.4% |
| Diluted Shares Outstanding (Cr) | 8 | 8 ▲ 0.0% |
| Other Comprehensive Income (Net of Tax) | -0 | -3 ▼ 2234.8% |
| Total Expenses (incl. D&A & Interest) | 808 | 898 ▲ 11.2% |
| Material Cost % of RevenueDerived | 56.59% | 44.42% |
| Employee Cost % of RevenueDerived | 8.31% | 8.78% |
| Other Cost % of RevenueDerived | 13.80% | 13.10% |
| Interest Coverage (x)Derived | 33.04x | 135.98x |
| Period | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|---|---|---|
| Revenue from Operations | 520 | 617 ▲ 18.6% | 717 ▲ 16.3% | 1,007 ▲ 40.3% | 1,339 ▲ 33.0% | |
| Sales Growth YoY %Derived | — | 18.57% | 16.33% | 40.34% | 33.02% | |
| Other Income | 3 | 4 ▲ 56.4% | 7 ▲ 73.4% | 17 ▲ 126.0% | 42 ▲ 145.6% | |
| Total Income | 523 | 621 ▲ 18.8% | 725 ▲ 16.7% | 1,024 ▲ 41.2% | 1,381 ▲ 34.9% | |
273 | 331 ▲ 21.3% | 412 ▲ 24.4% | 552 ▲ 34.1% | 566 ▲ 2.5% | ||
| Gross ProfitDerived | 247 | 286 ▲ 15.6% | 306 ▲ 7.0% | 455 ▲ 48.7% | 773 ▲ 70.1% | |
| Gross Margin %Derived | 47.55% | 46.35% | 42.62% | 45.16% | 57.74% | |
142 | 163 ▲ 14.9% | 177 ▲ 8.6% | 223 ▲ 25.6% | 293 ▲ 31.6% | ||
| EBITDA (Operating Profit)Derived | 105 | 123 ▲ 16.6% | 128 ▲ 4.8% | 232 ▲ 80.6% | 480 ▲ 107.0% | |
| OPM %Derived | 20.22% | 19.88% | 17.91% | 23.05% | 35.87% | |
16 | 15 ▼ 10.5% | -10 ▼ 168.4% | 33 ▲ 425.5% | 39 ▲ 19.5% | ||
| Profit Before Tax (PBT) | 91 | 112 ▲ 22.7% | 82 ▼ 27.0% | 216 ▲ 163.9% | 483 ▲ 123.3% | |
20 | 29 ▲ 48.1% | 33 ▲ 14.9% | 56 ▲ 67.9% | 126 ▲ 126.7% | ||
| Effective Tax %Derived | 21.33% | 25.75% | 40.53% | 25.79% | 26.18% | |
| Total Profit for Period | 72 | 83 ▲ 15.8% | 49 ▼ 41.5% | 160 ▲ 229.3% | 356 ▲ 122.2% | |
| Less: Non-controlling Interests | — | — | 6 | 2 ▼ 71.3% | 0 ▼ 93.3% | |
| Net Profit (Owner's PAT)Derived | 72 | 83 ▲ 15.8% | 43 ▼ 48.6% | 159 ▲ 271.1% | 356 ▲ 124.5% | |
| Net Profit Margin %Derived | 13.83% | 13.50% | 5.96% | 15.76% | 26.60% | |
| PAT Growth YoY %Derived | — | 15.77% | -48.65% | 271.06% | 124.46% | |
| Earnings Per Share (EPS ₹) | 9.87 | 11.43 ▲ 15.8% | 5.80 ▼ 49.3% | 19.39 ▲ 234.3% | 43.51 ▲ 124.4% | |
| Diluted Shares Outstanding (Cr) | 7 | 7 ▲ 0.0% | 7 ▲ 1.2% | 8 ▲ 11.0% | 8 ▲ 0.0% | |
| Other Comprehensive Income (Net of Tax) | 2 | 3 ▲ 62.4% | -7 ▼ 335.2% | -0 ▲ 98.1% | -3 ▼ 2234.8% | |
| Total Expenses (incl. D&A & Interest) | 431 | 509 ▲ 17.9% | 643 ▲ 26.4% | 808 ▲ 25.6% | 898 ▲ 11.2% | |
| Material Cost % of RevenueDerived | 54.28% | 56.08% | 61.35% | 56.59% | 44.42% | |
| Employee Cost % of RevenueDerived | 7.95% | 7.92% | 8.80% | 8.31% | 8.78% | |
| Other Cost % of RevenueDerived | 19.37% | 18.55% | 15.91% | 13.80% | 13.10% | |
| Interest Coverage (x)Derived | 14.84x | 45.71x | 18.93x | 33.04x | 135.98x |
Acutaas Chemicals segment analysis : revenue and profit mix.
Disclosed business segments at Acutaas Chemicals with their share of revenue and profit, switchable between consolidated and standalone reporting.
Acutaas Chemicals discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for Acutaas Chemicals Limited.
Our AI distills the core fundamental drivers supporting Acutaas Chemicals Limited, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
Acutaas Chemicals Limited's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
Latest quarterly EPS grew 110.9% YoY, signaling robust earnings acceleration and profitability
TTM revenue grew 40.3% YoY, reflecting strong top-line momentum and market demand
Quarterly operating margin 35.90% demonstrates exceptional pricing power and cost control
ROE 24.00% and ROCE 31.60% substantially exceed sector benchmarks, indicating efficient capital deployment
Debt-to-equity ratio 0.0002 with net debt negative ₹2,322.89 Cr, providing substantial financial flexibility
Key Risks.
P/E ratio 82.28x and EV/EBITDA 39.60x represent significant valuation premium versus peers
Dividend yield 0.05% offers minimal income appeal, limiting investor attraction for yield seekers
Negative free cash flow across multiple periods signals working capital strain and capex intensity
Promoter holding declined to 32.66%, raising governance and alignment concerns with minority shareholders
PEG ratio 4.35x signals overvaluation unless 25%+ EPS growth sustains multiple years
Flip Conditions.
Valuation risk. a P/E above 87 (~1.9× the sector multiple of 45.3) would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Return-quality risk. ROE below 19% would indicate weaker capital compounding.
Income thesis breaks if the dividend is cut or yield falls below 0.03%.
Acutaas Chemicals Limited peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Acutaas Chemicals Limited is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
Acutaas Chemicals Limited chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for Acutaas Chemicals Limited — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
Acutaas Chemicals Limited delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Acutaas Chemicals Limited over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Acutaas Chemicals Limited stood at 49.6% of traded volume, against a 20-day average of 53.3%.
Acutaas Chemicals announcements: results, concalls, ratings, M&A.
Filings Acutaas Chemicals sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Acutaas Chemicals files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 144 documents below.
General Updates
Acutaas Chemicals Limited has informed the Exchange about General Updates
General Updates
Acutaas Chemicals Limited has informed the Exchange about General Updates
Analysts/Institutional Investor Meet/Con. Call Updates
Acutaas Chemicals Limited has informed the Exchange about Schedule of meet
Analysts/Institutional Investor Meet/Con. Call Updates
Acutaas Chemicals Limited has informed the Exchange about Transcript
Copy of Newspaper Publication
Acutaas Chemicals Limited has informed the Exchange about Copy of Newspaper Publication
Investor decks & rating reports.
Acutaas Chemicals dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Acutaas Chemicals has declared, sequenced by announce and record date.
Acutaas Chemicals corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
Acutaas Chemicals insider trading: promoter and management activity.
Promoter, director and designated-employee transactions in Acutaas Chemicals as reported to SEBI — buying and selling signals from the people who know the business best.
Acutaas Chemicals insider activity below tracks 6 reported promoter, director and designated-employee transactions under SEBI Regulation 7(2).
| Insider | Category | Txn Date | Action | Quantity | Value (₹) | Price |
|---|---|---|---|---|---|---|
| Vijay Gosar | Insider | 27 Feb 2026 | buy | +500 | ₹10.72 L | ₹2,144.26 |
| Vijay Gosar | Insider | 27 Feb 2026 | buy | +500 | ₹10.72 L | ₹2,144.26 |
| Vijay Gosar | Insider | 27 Feb 2026 | buy | +500 | ₹10.72 L | ₹2,144.26 |
| Chetankumar Chhaganlal Vaghasia | Insider | 19 May 2025 | sell | −13.49 L | ₹150.4 Cr. | ₹1,115.00 |
| NARESHKUMAR RAMJIBHAI PATEL | Insider | 19 May 2025 | sell | −13.49 L | ₹150.4 Cr. | ₹1,115.00 |
| RAM MOHAN LOKHANDE | Insider | 31 Dec 2024 | sell | −400 | ₹8.52 L | ₹2,130.00 |
About Acutaas Chemicals Limited: business, sector, key facts.
What Acutaas Chemicals Limited does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Acutaas Chemicals Limited operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: ACUTAAS, BSE: 543349.
Acutaas Chemicals Limited is a prominent player in the pharmaceutical and specialty chemicals industry, headquartered in Surat, India. The company's core business revolves around the research, development, manufacturing, and global distribution of pharmaceutical intermediates. These intermediates serve as crucial building blocks for the synthesis of various active pharmaceutical ingredients (APIs).
Acutaas's pharmaceutical intermediate portfolio caters to a broad spectrum of therapeutic areas. Their products are integral components in the production of APIs for medications targeting conditions such as retroviral infections, inflammatory diseases, psychotic disorders, cancer, Parkinson's disease, depression, and blood clotting disorders. This highlights their significant contribution to the development and manufacture of essential medicines.
Beyond pharmaceutical applications, Acutaas Chemicals Limited also produces a range of specialty chemicals. These find applications in diverse sectors including agrochemicals (pesticides and herbicides), cosmetics, and polymers (plastics and resins). Specifically, they manufacture and supply parabens (used as preservatives), salicylic acid (with applications in various industries), and other custom-synthesized chemicals for various industrial uses. This diversification broadens their customer base and revenue streams.
The company's international reach is notable, with a significant portion of its production exported globally. This demonstrates their capability to meet international quality standards and successfully compete in a highly competitive global market. The company's history, dating back to its founding in 2004 as Ami Organics Limited and rebranding in May 2025, suggests a track record of growth and adaptation within the industry.
In summary, Acutaas Chemicals Limited operates as a vertically integrated chemical company. Their business model encompasses the entire value chain, from research and development to the global marketing and sales of diverse chemical products. Their focus on pharmaceutical intermediates, coupled with their expertise in specialty chemicals, positions them strategically within the rapidly evolving global chemical landscape.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- 3B Blackbio DX (3BBLACKBIO) Share PricePeer
- Abbott India (ABBOTINDIA) Share PricePeer
- Anlon Healthcare (AHCL) Share PricePeer
- Amanta Healthcare (AMANTA) Share PricePeer
- Ambalal Sarabhai Enterprises (AMBALALSA) Share PricePeer
- Top Gainers TodayScreener
- Other overvalued NSE stocksScreener
- Top quality scorecard stocksScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about Acutaas Chemicals Limited (ACUTAAS).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Acutaas Chemicals Limited (ACUTAAS)?
The current share price of Acutaas Chemicals Limited (ACUTAAS) is ₹3,313.40. Today, the stock has gained by ₹140.40 (4.42%), trading in a range of ₹3,138.00 to ₹3,325.00. The stock opened at ₹3,189.90 with a trading volume of 4,09,528 shares.
02Is Acutaas Chemicals Limited stock a good investment for long-term?
Acutaas Chemicals Limited can be considered for long-term investment based on several factors. The company has a market capitalization of ₹27,017.47 Cr., P/E ratio of 67.17, ROE of 24%, and ROCE of 31.6%. The dividend yield stands at 0.05%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Acutaas Chemicals Limited stock?
The 52-week high price of Acutaas Chemicals Limited (ACUTAAS) is ₹3,740.00, while the 52-week low is ₹1,302.00. Currently trading at ₹3,313.40, the stock is 154.49% above its 52-week low and 11.41% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Acutaas Chemicals Limited stock at the current price?
Whether to buy Acutaas Chemicals Limited stock at ₹3,313.40 depends on multiple factors. The stock is currently trading with a P/E ratio of 67.17 and P/B ratio of 15.69. Today's performance shows a gain of 4.42%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Acutaas Chemicals Limited and when is the next dividend?
Acutaas Chemicals Limited offers a dividend yield of 0.05%, which means for every ₹100 invested at the current price of ₹3,313.40, you can expect to receive approximately ₹0.05 annually as dividends. The face value of the stock is ₹5.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Acutaas Chemicals Limited?
Acutaas Chemicals Limited's key financial metrics include: P/E Ratio: 67.17, P/B Ratio: 15.69, ROE: 24%, ROCE: 31.6%, Dividend Yield: 0.05%, EPS: ₹34.90, Book Value: ₹201.93, and Debt-to-Equity: 0.02. The company's market cap stands at ₹27,017.47 Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Acutaas Chemicals Limited stock performing today in the market?
Acutaas Chemicals Limited stock opened at ₹3,189.90 and is currently trading at ₹3,313.40, showing a gain of ₹140.40 (4.42%). The intraday high is ₹3,325.00 and low is ₹3,138.00. The trading volume stands at 4,09,528 shares, indicating moderate market participation today.
08What is the P/E ratio of Acutaas Chemicals Limited and what does it indicate?
Acutaas Chemicals Limited has a Price-to-Earnings (P/E) ratio of 67.17, which means investors are willing to pay 67.17 for every ₹1 of earnings. With an EPS of ₹34.90, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Acutaas Chemicals Limited (ACUTAAS) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.